Compare MXL & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | SRPT |
|---|---|---|
| Founded | 2003 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2009 | 2000 |
| Metric | MXL | SRPT |
|---|---|---|
| Price | $93.87 | $17.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 29 |
| Target Price | ★ $41.67 | $25.85 |
| AVG Volume (30 Days) | ★ 4.9M | 2.6M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.08 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | $478,596,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $10.70 | N/A |
| P/E Ratio | ★ N/A | $5.99 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $11.26 | $10.42 |
| 52 Week High | $106.28 | $43.92 |
| Indicator | MXL | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 42.49 |
| Support Level | $15.36 | $17.11 |
| Resistance Level | $104.27 | $18.10 |
| Average True Range (ATR) | 11.84 | 0.77 |
| MACD | -2.00 | -0.09 |
| Stochastic Oscillator | 52.17 | 28.85 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.